CHGA Antibody

What is Chromogranin A (CHGA) and what is its biological significance?

Chromogranin A is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins found in secretory vesicles of neurons and endocrine cells . It functions as a precursor to several biologically active peptides including vasostatin, pancreastatin, and parastatin, which act as autocrine or paracrine negative modulators of the neuroendocrine system . CHGA plays crucial roles in:

• Facilitating the regulated endocrine secretion of monoamines

• Acting as a storage capacity generating protein in vesicles

• Modulating innate immune responses

• Regulating granule biogenesis in endocrine cells through its cleaved peptide serpinin

CHGA-derived peptides are involved in numerous physiological processes including inhibition of glucose-induced insulin release (pancreastatin), inhibition of catecholamine release (catestatin), and antibacterial activity against various Gram-positive and Gram-negative bacteria .

While the calculated molecular weight of the canonical CHGA protein is approximately 50-51 kDa, the observed molecular weight in Western blot applications is typically 70-85 kDa due to extensive post-translational modifications . Specific observed weights from various antibody sources include:

• 80 kDa on Western blot for Cell Signaling Technology antibody #60893

• 70 kDa observed molecular weight for some anti-CHGA antibodies

This discrepancy between calculated and observed weights is primarily due to glycosylation and other post-translational modifications .

In which cell and tissue types is CHGA most highly expressed?

CHGA expression is predominantly observed in:

• Chromaffin cells of the adrenal medulla (where CHGA was originally discovered)

• Neuroendocrine cells throughout the body, including:

  • Large and small intestine neuroendocrine cells

  • Enterochromaffin (EC) cells and EC-like cells in the gastrointestinal tract

  • Pancreatic islets and endocrine cells

  • Pituitary gland cells (gonadotrophs, thyrotrophs, and some corticotrophs)

CHGA protein can be detected in cerebrospinal fluid and as a secreted marker in serum . In the gastrointestinal tract, CHGA expression patterns vary by region, with strong expression in the stomach and colon but weaker expression in the small intestine .

How do enzymatic modifications affect CHGA epitope recognition and antibody binding?

Post-translational modifications of CHGA can significantly alter antibody recognition and potentially create neo-antigens relevant to autoimmune conditions. A notable example involves transglutaminase (TGase) treatment:

• TGase treatment of the WE14 peptide (a naturally occurring cleavage product of CHGA) dramatically increases its antigenic activity

• In studies examining type 1 diabetes (T1D), TGase-modified WE14 showed increased reactivity in some patients compared to unmodified WE14

• The modification involves crosslinking rather than deamidation, which enhances epitope recognition

These findings suggest that researchers should consider the potential role of post-translational modifications when analyzing CHGA in different disease contexts, particularly autoimmune conditions where modified self-antigens may drive pathology.

What is the role of CHGA in type 1 diabetes research and what methodological approaches are used?

CHGA has emerged as an important autoantigen in type 1 diabetes (T1D) research:

• The WE14 peptide derived from CHGA has been identified as a target for autoreactive CD4 T cells in T1D patients

• T cell responses to WE14 are dose-dependent and significantly different between T1D patients and controls

• Methodological approaches for studying these responses include:

  • Indirect CD4 ELISPOT assay for IFN-γ to detect T cell responders to CHGA antigens

  • Testing responses to both unmodified WE14 and TGase-modified WE14

  • Calculating stimulation index (SI) for each peptide/antigen and using statistical analysis to compare patient and control responses

These methodologies enable researchers to investigate CHGA as a target antigen in autoimmune diabetes and potentially develop antigen-specific tolerance induction strategies.

How can CHGA antibodies be used in the characterization of neuroendocrine tumors?

CHGA antibodies serve as valuable tools for identifying and characterizing neuroendocrine tumors (NETs):

• CHGA is considered an excellent marker for carcinoid tumors, pheochromocytomas, paragangliomas, and other neuroendocrine tumors

• Co-expression patterns with other markers can provide diagnostic insights:

  • Co-expression of CHGA and neuron-specific enolase (NSE) is common in neuroendocrine neoplasms

  • Co-expression of certain keratins and CHGA indicates neuroendocrine lineage

  • Strong CHGA staining with absence of keratin staining may indicate paraganglioma

For optimal characterization of NETs, researchers should consider panel approaches combining CHGA with other neuroendocrine markers and use appropriate controls to ensure specificity.

What are the optimal antigen retrieval and immunostaining protocols for CHGA immunohistochemistry?

For effective CHGA immunohistochemistry:

Antigen Retrieval Methods:

• Heat-induced epitope retrieval in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

• Alternative method: Citrate buffer (pH 6.0) can be used for some antibody clones

Immunostaining Protocol:

• Deparaffinize and rehydrate tissue sections

• Perform antigen retrieval as described above

• Block with 2% BSA in PBS

• Incubate with primary anti-CHGA antibody (typical dilutions 1:50-1:2000) overnight at 4°C

• Wash sections in PBS (3 × 2 min)

• Incubate with appropriate secondary antibody (typically 1:200 dilution) for 1 hour at room temperature

• Wash and mount with appropriate mounting medium (e.g., Prolong Gold Antifade Reagent with DAPI for fluorescence)

For colonic sections and specific antibody clones (e.g., sc-1488 anti-CHGA), antigen retrieval is particularly critical for optimal staining .

How can researchers generate and utilize CHGA reporter systems for studying neuroendocrine cells?

CHGA reporter systems provide valuable tools for studying neuroendocrine cell populations:

• Transgenic reporter mice expressing humanized Renilla reniformis green fluorescent protein (hrGFP) under the control of CHGA transcriptional elements have been developed

• These systems allow visualization of CHGA-expressing cells throughout the GI tract, pancreas, pituitary, and adrenal medulla

• Methods for utilizing such systems include:

  • Direct fluorescence visualization of hrGFP-positive cells

  • Antibody enhancement of weak signals using anti-hrGFP antibodies

  • Fluorescence-activated cell sorting (FACS) of reporter-positive cells for downstream analysis

In the gastrointestinal tract, such reporter systems revealed that CHGA expression is predominantly found in monoamine-storing cells, making these tools particularly valuable for studying histamine and serotonin-secreting enteroendocrine cells .

What controls should be included when validating CHGA antibody specificity?

Proper validation of CHGA antibodies requires several controls:

Positive Controls:

• Adrenal medulla tissue (where CHGA was originally discovered)

• Pituitary gland sections

• PC-12 cells (commonly used as a positive control in Western blot)

• Known neuroendocrine tumor samples

Negative Controls:

• Tissues known to lack CHGA expression (liver, kidney, spleen, etc.)

• Isotype-matched control antibodies used at the same concentration

• Blocking peptide controls (using the immunogen peptide to demonstrate specificity)

Cross-validation:

• Compare multiple anti-CHGA antibody clones targeting different epitopes

• Validate results using alternative detection methods (IHC, WB, IF)

• For transgenic reporter models, confirm co-localization of reporter signal with CHGA immunoreactivity

What approaches can be used to maximize signal-to-noise ratio when using CHGA antibodies?

To achieve optimal signal-to-noise ratio with CHGA antibodies:

• Antibody Dilution Optimization:

  • Test a range of dilutions (e.g., 1:50-1:2000 for IHC applications)

  • Create a dilution series to identify the optimal concentration that maximizes specific signal while minimizing background

• Blocking Strategies:

  • Use 2% BSA in PBS for effective blocking

  • Consider adding serum from the species in which the secondary antibody was raised

• Background Reduction:

  • For fluorescent applications, be aware that blue fluorescent dyes like CF®405S can give higher non-specific background than other dye colors

  • Consider autofluorescence quenching steps when working with tissues high in endogenous fluorescence

• Signal Enhancement:

  • For weak CHGA signals (common in small intestine), consider signal amplification methods

  • Use high-affinity detection systems (e.g., polymer-based secondary detection)

• Antigen Retrieval Optimization:

  • Compare different antigen retrieval methods (EDTA-based versus citrate-based)

  • Optimize retrieval time and temperature for specific tissue types

How are CHGA antibodies utilized in influenza vaccine development research?

CHGA antibodies play an unexpected role in influenza vaccine research through immunological techniques:

• In studies of chimeric hemagglutinin-based (cHA) vaccination strategies, researchers evaluate the protective activity of vaccine-elicited IgG antibodies

• CHGA antibodies may be used in these contexts for:

  • Characterizing neuroendocrine responses to vaccination

  • Analyzing cellular immune responses via immunological assays

  • Studying how Fc-FcγR interactions contribute to protection

Research has shown that IgG antibodies elicited upon cHA vaccination completely protected FcγR humanized mice against lethal influenza virus challenge, while no protection was evident in FcγR-deficient mice , highlighting the importance of Fc-mediated effector functions in vaccine protection.

What are the current methodological approaches for studying CHGA as a T cell antigen?

Research on CHGA as a T cell antigen, particularly in type 1 diabetes, employs several methodological approaches:

• T Cell Response Assays:

  • Indirect CD4 ELISPOT assay for IFN-γ to detect T cell responders to CHGA antigens

  • Testing responses at multiple peptide concentrations to establish dose-dependency

• Peptide Modification Strategies:

  • Enzymatic modification of WE14 peptide using transglutaminase to enhance its immunogenicity

  • Comparison of T cell responses to both modified and unmodified peptides

• Sample Processing:

  • Isolation of peripheral blood mononuclear cells (PBMCs) from patient and control samples

  • HLA typing to stratify subjects based on genetic risk factors (particularly HLA-DQ8)

• Controls and Analysis:

  • Using both first-degree relatives without antibodies and HLA-matched general population controls

  • Calculating stimulation indices and performing statistical analysis using unpaired two-tailed Student's T tests

How can CHGA antibodies be integrated into multiplex immunoassay panels?

For effective integration of CHGA antibodies into multiplex panels:

• Panel Design Considerations:

  • Combine CHGA with other neuroendocrine markers such as synaptophysin and neuron-specific enolase (NSE)

  • Include markers that distinguish different neuroendocrine cell types (e.g., insulin, glucagon, somatostatin for pancreatic cells)

• Technical Optimization:

  • Select primary antibodies raised in different host species to avoid cross-reactivity

  • Use fluorophore-conjugated secondary antibodies with minimal spectral overlap

  • Consider directly conjugated primary antibodies for reduced complexity

• Validation Approaches:

  • Perform single-marker controls alongside multiplex panels

  • Include appropriate blocking steps to prevent non-specific binding

  • Validate multiplex results against established single-marker protocols

Researchers have successfully applied these approaches to characterize the diverse neuroendocrine cell populations in tissues such as the gastrointestinal tract, where CHGA expression correlates with specific subpopulations of endocrine cells .

What are common issues encountered when using CHGA antibodies and how can they be resolved?

What quality control measures should be implemented when working with CHGA antibodies?

Rigorous quality control for CHGA antibody applications should include:

• Antibody Validation:

  • Confirm antibody specificity using positive and negative controls

  • Validate across multiple applications (WB, IHC, IF) when possible

  • Compare results with multiple anti-CHGA antibody clones

• Technical Controls:

  • Include isotype controls at matching concentrations

  • Run no-primary-antibody controls to assess secondary antibody specificity

  • For fluorescence applications, include autofluorescence controls

• Reference Standards:

  • Use established cell lines (e.g., PC-12) as reference standards

  • Include well-characterized tissue sections with known CHGA expression patterns

• Documentation:

  • Record lot numbers and validate each new lot against previous results

  • Document all protocol parameters (dilutions, incubation times, etc.)

  • Maintain image acquisition settings for consistency across experiments

• Specialized Considerations:

  • For flow cytometry, use appropriate compensation controls

  • For multiplex applications, include single-stain controls to assess spectral overlap

By implementing these comprehensive quality control measures, researchers can ensure reliable and reproducible results when working with CHGA antibodies across various experimental contexts.